- Home
- NRIX vs VRE Comparison
NRIX vs VRE Comparison
Compare NRIX & VRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NRIX | VRE |
|---|---|---|
| Founded | 2009 | 1949 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | 2020 | 1995 |
Fundamental Metrics
Financial Performance| Metric | NRIX | VRE |
|---|---|---|
| Price | $15.03 | $18.87 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 3 |
| Target Price | ★ $29.46 | $18.67 |
| AVG Volume (30 Days) | 704.0K | ★ 2.2M |
| Earning Date | 05-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 1.70% |
| EPS Growth | N/A | ★ 420.00 |
| EPS | N/A | ★ 0.80 |
| Revenue | $76,987,000.00 | ★ $288,434,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $26.32 | $2.87 |
| P/E Ratio | ★ N/A | $23.60 |
| Revenue Growth | ★ 99.31 | 6.40 |
| 52 Week Low | $8.18 | $13.69 |
| 52 Week High | $22.50 | $18.89 |
Technical Indicators
Market Signals| Indicator | NRIX | VRE |
|---|---|---|
| Relative Strength Index (RSI) | 39.68 | 79.53 |
| Support Level | $14.91 | $14.43 |
| Resistance Level | $16.47 | $18.89 |
| Average True Range (ATR) | 0.82 | 0.03 |
| MACD | 0.04 | -0.08 |
| Stochastic Oscillator | 23.18 | 66.67 |
Price Performance
Historical ComparisonAbout NRIX Nurix Therapeutics Inc.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
About VRE Veris Residential Inc.
Veris Residential Inc is a fully-integrated, self-administered and self-managed real estate investment trust (REIT). The company owns and operates a real estate portfolio comprised predominantly of multifamily rental properties located mainly in the Northeast and Class A office properties. The company performs substantially all real estate management, leasing, acquisition and development on an in-house basis. The properties are in three states in the Northeast, plus the District of Columbia. The company operates in two industry segments multifamily real estate & services and commercial & other real estate. The majority of revenue is from Multifamily real estate services.